CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T the...

Full description

Bibliographic Details

Published in:	Heliyon
Main Authors:	Jie Liu, Mengyuan Xu, Xiaoqian Zhang, Zhuo Zhang, Tao Zhong, Hongjuan Yu, Yueyue Fu, Hongbin Meng, Jiawei Feng, Xindi Zou, Xueying Han, Liqing Kang, Lei Yu, Limin Li
Format:	Article
Language:	English
Published:	Elsevier 2024-07-01
Subjects:	B-cell acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation, Chimeric antigen receptor-T Refractory Relapsed
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024099687